FDA Clearance Excitement: Recent buzz on X about Tempus AI, Inc. (TEM) has centered on the FDA 510(k) clearance for their new AI-driven diagnostic tools. Many users view this as a significant milestone for precision medicine, especially in oncology applications. The news has sparked optimism about the company’s growth potential.
Earnings and Stock Dip: Discussions on X also focus on TEM’s latest earnings report, which showed strong revenue growth and raised guidance for 2025. However, a post-earnings stock decline has led some to question market confidence despite the positive numbers. This mix of hope and skepticism keeps the conversation dynamic.
Short Seller Concerns: A resurfaced short seller report questioning revenue sources has added fuel to the debate on X. While some argue the negativity is already reflected in the stock price, others express caution over potential volatility tied to high short interest. The tension creates a gripping narrative for followers.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI, Inc. Insider Trading Activity
Tempus AI, Inc. insiders have traded $TEM stock on the open market 124 times in the past 6 months. Of those trades, 0 have been purchases and 124 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 70 sales selling 1,864,287 shares for an estimated $138,924,039.
- RYAN FUKUSHIMA (Chief Operating Officer) has made 0 purchases and 20 sales selling 72,559 shares for an estimated $5,175,884.
- THEODORE LEONSIS has made 0 purchases and 2 sales selling 64,000 shares for an estimated $4,592,200.
- ERIK PHELPS (EVP & Chief Admin & Legal Off) has made 0 purchases and 8 sales selling 58,514 shares for an estimated $4,228,713.
- ANDREW POLOVIN (EVP and General Counsel) has made 0 purchases and 9 sales selling 18,413 shares for an estimated $1,281,456.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 4 sales selling 14,785 shares for an estimated $1,037,605.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 4 sales selling 3,738 shares for an estimated $262,337.
- JENNIFER A DOUDNA has made 0 purchases and 3 sales selling 3,109 shares for an estimated $207,489.
- DAVID R EPSTEIN has made 0 purchases and 4 sales selling 1,240 shares for an estimated $85,919.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tempus AI, Inc. Hedge Fund Activity
We have seen 250 institutional investors add shares of Tempus AI, Inc. stock to their portfolio, and 166 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC removed 4,030,697 shares (-94.7%) from their portfolio in Q3 2025, for an estimated $325,317,554
- NEA MANAGEMENT COMPANY, LLC removed 2,615,979 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $166,219,305
- BLACKROCK, INC. added 2,597,838 shares (+62.8%) to their portfolio in Q3 2025, for an estimated $209,671,504
- BAILLIE GIFFORD & CO removed 2,401,588 shares (-19.9%) from their portfolio in Q3 2025, for an estimated $193,832,167
- VANGUARD GROUP INC added 1,706,837 shares (+22.1%) to their portfolio in Q3 2025, for an estimated $137,758,814
- D. E. SHAW & CO., INC. added 1,605,757 shares (+380.8%) to their portfolio in Q3 2025, for an estimated $129,600,647
- BANK OF AMERICA CORP /DE/ added 1,277,244 shares (+112.9%) to their portfolio in Q3 2025, for an estimated $103,086,363
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Tempus AI, Inc. Government Contracts
We have seen $18,460,020 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975
- TUMOR NORMAL MATCHED GENOMIC TESTING SERVICES: $5,718,045
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Tempus AI, Inc. Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/25/2025
- Morgan Stanley issued a "Overweight" rating on 11/11/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/07/2025
- Canaccord Genuity issued a "Buy" rating on 11/05/2025
- Guggenheim issued a "Buy" rating on 09/26/2025
To track analyst ratings and price targets for Tempus AI, Inc., check out Quiver Quantitative's $TEM forecast page.
Tempus AI, Inc. Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 8 analysts offer price targets for $TEM in the last 6 months, with a median target of $92.0.
Here are some recent targets:
- Mark Massaro from BTIG set a target price of $105.0 on 11/25/2025
- David Westenberg from Piper Sandler set a target price of $80.0 on 11/11/2025
- Tejas Savant from Morgan Stanley set a target price of $80.0 on 11/11/2025
- Yi Chen from HC Wainwright & Co. set a target price of $89.0 on 11/07/2025
- Ryan MacDonald from Needham set a target price of $100.0 on 11/05/2025
- Kyle Mikson from Canaccord Genuity set a target price of $95.0 on 11/05/2025
- Subbu Nambi from Guggenheim set a target price of $95.0 on 09/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
